Egypt to offer home made covid-19 drug, Remdesivir for public sale at $42.55
London, July 22, 2020 (AltAfrica)-Egypt’s Rameda Pharmaceutical said it will make its intravenous Remdesivir, an antiviral drug used for treating critical COVID-19 cases, available to the public starting September, after receiving an official notice from the Egyptian Drug Authority (EDA) on the drug’s commercial prices.
In a disclosure to the bourse on Tuesday, the company said it was notified by the EDA on the commercial price of Remdesivir powder vials used in the treatment of coronavirus patients, setting the price at EGP 680 ($42.55) per vial under the brand name Remdesivir-Rameda.
Rameda will be the first company in Egypt to produce ‘Remdesivir’ powder in vial form, which can be stored at room temperature, after it received necessary approvals from the EDA last June, according to the statement.
Remdesivir, originally developed to treat Ebola, appears to shorten the recovery time of COVID-19 patients.
The experimental drug has recently been authorised for the treatment of certain hospitalised patients in several countries including the US, the UK and Japan.
The Egyptian drug manufacturer also said its drug Anviziram will be sold for EGP 1,260 ($78.85) per 40-tablet pack in accordance with a decision by the EDA.
Anviziram contains the active pharmaceutical ingredient Favipiravir, which is the generic form of the antiviral medicine released under the brand name Avigan in Japan.
No coronavirus vaccine has been developed yet, but many countries are conducting human trials for several existing antiviral drugs to test their efficacy.
Some of the most talked-about drugs are the Russian-approved Avifavir, the American Remdesivir and the ChAdOx1 nCoV-19 vaccine from Oxford, UK
Avifavir, also known by the name Avigan, is based on the Japanese influenza drug Favipiravir which was approved for manufacturing and sale in Japan in 2014 and became a generic drug in 2019.
Remedisvir — originally developed to treat hepatitis C and was then tested against Ebola virus — is manufactured by the US Gilead Sciences Inc which helped, according to clinical trials, hospitalised coronavirus patients recover more quickly.
The Oxford vaccine called ChAdOx1 nCoV-19 vaccine appears safe and triggers an immune response. Trials involving 1,077 people showed the injection led to them making antibodies and T-cells that can fight coronavirus.
The findings are hugely promising, but it is still too soon to know if this is enough to offer protection and larger trials are under way.
The UK has already ordered 100 million doses of the vaccine.
Egypt has been seeing a significant drop in detected coronavirus cases, registering less than 1,000 daily cases in the past few days.
Egypt recorded 627 new coronavirus cases on Monday, bringing the total infection tally to 88,402, including 4,352 fatalities since the outbreak of the virus in mid-February. Source